Performance of the Centers for Medicare & Medicaid Services' Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose
To address the growing problem of opioid overuse and abuse in the Medicare population, the Centers for Medicare & Medicaid Services (CMS) launched an Overutilization Monitoring System in 2013, requiring its Part D plan sponsors to identify beneficiaries who are at high risk of opioidrelated adverse events based on opioid overutilization criteria and to implement interventions. 1 Whether the criteria, which depend on prescription-dispensing data, are accurate as a clinical marker for classifying beneficiaries with opioid use disorder (OUD) or overdose is unknown.
Methods | We used the 5% Medicare sample from 2011 through 2014 to estimate the sensitivity, specificity, and positive predictive value of the CMS opioid overutilization criteria in correctly identifying prescription opioid users at risk of OUD or overdose in three 6-month cycles (ie, Januar y 1-June 30, April 1-September 30, and July 1-December 31) in each calendar year. We studied the performance measures over time, hypothesizing that accuracy might change with increasing efforts to combat the opioid crisis. 2 Concordant with the most recent (2017) reporting requirements for Part D plans, we used 3 overlapping 6-month cycles per year.
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In each 6-month cycle, eligible patients were required to have at least 1 prescription opioid filled; be continuously enrolled in Parts A, B, and D; and have no cancer nor be receiving hospice care. 1 We identified eligible beneficiaries who met CMS criteria as opioid overutilizers (ie, receiving prescription opioids with a mean daily morphine equivalent dose ≥90 mg and from >3 prescribers and >3 pharmacists or receiving a prescription of opioids with a mean daily morphine equivalent dose of ≥90 mg by >4 prescribers) 1 and those who had a diagnosis of OUD or overdose 3 in the same 6 months plus the subsequent 12 months to account for delays in OUD diagnoses. Linear regression was used to determine trends over time (SAS version 9.4; SAS Institute Inc). Statistical significance was defined as a 2-sided P<.05. This study was approved by the University of Florida Institutional Review Board with a waiver of informed consent.
Results | We identified between 142 036 and 190 320 eligible beneficiaries prescribed opioids across the 6-month measurement cycles from 2011 through 2014. The proportion of beneficiaries who met CMS overutilization criteria during any 6-month cycle ranged from 0.37% to 0.58%. The proportion who had a diagnosis of OUD or overdose during the 18-month follow-up increased from 3.91% in the first cycle to 7.55% in the last. We observed low sensitivity of the criteria, ranging from 4.96% (95% CI, 4.42%-5.58%) at the beginning of the study period to 2.52% (95% CI, 2.26%-2.81%) at the end (P for trend <.001) and positive predictive values ranged from 35.20% (95% CI, 32.14%-38.38%) to 50.94% (95% CI, 47.00%-54.86%; P for trend <.001). Specificity was greater than 99% in all cycles (Table) .
Discussion | Although the CMS criteria may target patients at true risk of OUD or overdose, they missed the majority of patients with OUD or overdose and flagged more than half of opioid prescription users as high risk who were not diagnosed as having OUD or overdose. The small positive Sensitivity is calculated by dividing the number of patients who were diagnosed as having OUD or overdose and met CMS criteria by the total number of patients who were diagnosed as having OUD or overdose. Specificity is calculated by dividing the number of patients who were not diagnosed as having OUD or overdose and did not meet CMS criteria by the total number of patients who were not diagnosed as having OUD or overdose. The positive predictive value is calculated by dividing the number of patients who were diagnosed as having OUD or overdose and met CMS criteria by the total number of those who met CMS criteria.
f Test for trend was examined using linear regression. Sensitivity was P<.001; specificity, P=.001; and positive predictive value, P <.001.
Letters predictive value is attributable partly to the low OUD prevalence in the Medicare sample. For identified high-risk beneficiaries, CMS requires its Part D plan sponsors to implement patient-specific utilization review, case management, and dose-dependent safety alerts or reimbursement rejections at the time of opioid dispensing. 1, 4 The Substance Use-Disorder Prevention That
Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, which was signed into law on October 24, 2018, allows CMS to refuse payment for opioids prescribed to beneficiaries who are identified as high risk unless their prescriptions are issued by a designated clinician.
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Based on this study, the CMS criteria's low sensitivity suggests different approaches are needed to identify high-risk patients and prevent or treat OUD. The mechanisms explaining the present findings likely include reliance on prescription opioid data and failure to capture illicit opioid use, which is surpassing prescription opioids in their contribution to opioid overdoses. 6 Because the CMS criteria are confined to patients who received opioid prescriptions, these results do not extend to patients with OUD or overdose who solely used illicit opioid sources; thus, reported incidence rates and sensitivity results are likely underestimated.
COMMENT & RESPONSE

Age of Initiation of Cervical Cancer Screening
To the Editor The US Preventive Services Task Force (USPSTF) recently recommended screening for cervical cancer every 3 years with cervical cytology in women aged 21 to 29 years (A recommendation). 1 I question why cervical screening is recommended starting at age 21 years rather than 25 years. For unscreened women younger than 25 years, the incidence of invasive cervical cancer is extremely low. Many other countries with evidence-based national policies start screening at age 25 years or even 30 years. 2, 3 The task force did not appear to consider the question of starting age. In addition, although the report recognized that women are at risk "because of potential exposure to high-risk HPV [human papillomavirus] types through sexual intercourse," it did not excuse from screening women who have never been sexually active. Because it takes years for HPV infection to transform to neoplasia, women do not need screening until at least a few years after initiation of sexual activity.
Even for screened women, there is good evidence that cytology screening of young women decreases their small risk by only a fraction. 4 The benefit of starting screening for cervical cancer at age 21 years must be weighed against the harms.
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As the report noted, in the first few years after sexual activity, women are likely to demonstrate infections with HPV, and some of these women will be treated with cervical cone biopsies. For young women who have not had their family, cone biopsies are associated with early pregnancy loss or premature labor.
